NASDAQ: SRRK
Scholar Rock Holding Corp Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their SRRK stock forecasts and price targets.

Forecast return on equity

Is SRRK forecast to generate an efficient return?

Company
34.05%
Industry
167.34%
Market
90.24%
SRRK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRRK forecast to generate an efficient return on assets?

Company
26.09%
Industry
44.32%
SRRK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRRK earnings per share forecast

What is SRRK's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$2.64
Avg 2 year Forecast
-$1.48
Avg 3 year Forecast
-$0.31

SRRK revenue forecast

What is SRRK's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$7.0M
Avg 2 year Forecast
$153.8M
Avg 3 year Forecast
$354.6M

SRRK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRRK$38.59N/AN/A
ACAD$21.89$28.19+28.77%Buy
ZLAB$34.28$54.28+58.33%Buy
VKTX$31.63$79.00+149.76%Strong Buy
MRUS$55.62$91.38+64.28%Strong Buy

Scholar Rock Holding Stock Forecast FAQ

What is SRRK's earnings growth forecast for 2025-2027?

(NASDAQ: SRRK) Scholar Rock Holding's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Scholar Rock Holding's earnings in 2025 is -$264,164,000.On average, 9 Wall Street analysts forecast SRRK's earnings for 2025 to be -$250,656,284, with the lowest SRRK earnings forecast at -$312,370,899, and the highest SRRK earnings forecast at -$204,132,958. On average, 9 Wall Street analysts forecast SRRK's earnings for 2026 to be -$140,623,872, with the lowest SRRK earnings forecast at -$193,688,946, and the highest SRRK earnings forecast at $3,797,822.

In 2027, SRRK is forecast to generate -$29,594,532 in earnings, with the lowest earnings forecast at -$109,187,396 and the highest earnings forecast at $104,440,118.

If you're new to stock investing, here's how to buy Scholar Rock Holding stock.

What is SRRK's revenue growth forecast for 2025-2027?

(NASDAQ: SRRK) Scholar Rock Holding's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Scholar Rock Holding's revenue in 2025 is $0.On average, 7 Wall Street analysts forecast SRRK's revenue for 2025 to be $668,416,756, with the lowest SRRK revenue forecast at $153,811,810, and the highest SRRK revenue forecast at $1,898,911,240. On average, 7 Wall Street analysts forecast SRRK's revenue for 2026 to be $14,601,108,307, with the lowest SRRK revenue forecast at $9,494,556,200, and the highest SRRK revenue forecast at $21,172,860,326.

In 2027, SRRK is forecast to generate $33,666,556,938 in revenue, with the lowest revenue forecast at $22,008,381,272 and the highest revenue forecast at $42,915,394,024.

What is SRRK's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SRRK) forecast ROA is 26.09%, which is lower than the forecast US Biotechnology industry average of 44.32%.

What is SRRK's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SRRK) Scholar Rock Holding's current Earnings Per Share (EPS) is -$2.54. On average, analysts forecast that SRRK's EPS will be -$2.64 for 2025, with the lowest EPS forecast at -$3.29, and the highest EPS forecast at -$2.15. On average, analysts forecast that SRRK's EPS will be -$1.48 for 2026, with the lowest EPS forecast at -$2.04, and the highest EPS forecast at $0.04. In 2027, SRRK's EPS is forecast to hit -$0.31 (min: -$1.15, max: $1.10).

What is SRRK's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SRRK) forecast ROE is 34.05%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.